BioSpace News Archive

VBL Therapeutics announced that it will host a conference call and live audio webcast on Thursday, November 14 at 8:30am Eastern Time to report third quarter and nine-months ended September 30, 2019 financial results and to provide a corporate update.

Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced that it will be presenting findings from two nonclinical studies at the upcoming American Association of Pharmaceutical Scientists 2019 PharmSci 360 conference taking place in San Antonio, Texas at the Henry B. Gonzalez Convention Center, November 3–6, 2019

Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report third quarter 2019 financial results and provide a corporate update before market open on Thursday, November 7, 2019.

HTG Molecular Diagnostics, Inc., a diagnostic company whose mission is to advance precision medicine, announced that it will report its financial results for the third quarter ended September 30, 2019 after the market close on Tuesday, November 12, 2019.

Landmark Recovery, a premier drug and alcohol rehab organization, announces a new relationship with Sabra Health Care REIT, Inc.

Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T-cell therapies to treat cancers, announced a poster presentation at the Society for Immunotherapy of Cancer 34th Annual Meeting, November 6-10, 2019, in National Harbor, Maryland.

First-in-human phase 1/2 study evaluating DS-7300, a B7-H3 targeting ADC, in patients with advanced/unresectable or metastatic solid tumors

Animal model for the study of Chronic Myocardial Infarction indicates, for the first time, regenerative potential in a pig’s heart using uncultured autologous adipose-derived regenerative cells prepared at point of care.

Caladrius Biosciences, Inc., a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies in select cardiovascular and autoimmune diseases, announced that the Company will participate in the following conferences in November

Collaboration Gives Beam Exclusive License for Use of Novel Emerging Gene Editing Technology to Treat Sickle Cell Disease and for Single-Base Transition Mutations